---
title: "CSPC PHARMA's SYH2082 injection approved for clinical use in the United States"
description: "CSPC PHARMA's SYH2082 injection has been approved by the U.S. FDA, allowing for clinical trials in the United States. This drug is a GLP-1/GIP receptor dual biased agonist, designed to enhance efficac"
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/276035702.md"
published_at: "2026-02-16T06:11:03.000Z"
---

# CSPC PHARMA's SYH2082 injection approved for clinical use in the United States

> CSPC PHARMA's SYH2082 injection has been approved by the U.S. FDA, allowing for clinical trials in the United States. This drug is a GLP-1/GIP receptor dual biased agonist, designed to enhance efficacy and prolong action time by selectively activating the cAMP pathway. Combined with long half-life modifications and long-acting formulation technology, the goal is to achieve sustained weight loss

CSPC PHARMA (01093.HK) announced that the GLP-1/GIP receptor dual agonist long-acting injection (SYH2082 injection) developed by the group has been approved by the U.S. Food and Drug Administration to conduct clinical trials in the United States.

The group stated that SYH2082 selectively activates the cAMP pathway, reduces β-arrestin recruitment, thereby decreasing receptor internalization and desensitization, enhancing efficacy and prolonging duration of action. At the same time, SYH2082 combines long half-life modification platform technology and long-acting formulation platform technology, aiming to achieve sustained weight loss during the dosing interval

### Related Stocks

- [01093.HK - CSPC PHARMA](https://longbridge.com/en/quote/01093.HK.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| 石藥集團獲得監管機構的批准以啓動藥物試驗 | 石藥集團獲得監管批准開始藥物試驗 | [Link](https://longbridge.com/en/news/276035104.md) |
| 石藥集團有限公司獲得美國食品藥品監督管理局的批准，可以在美國開展臨牀試驗 | CSPC 製藥集團有限公司已獲得 FDA 批准，在美國進行其 GLP-1/GIP 受體雙偏向激動劑 SYH2082 注射劑的臨牀試驗。這種設計為每月一次的長效注射劑旨在提高患者的依從性，並支持持續的減重。前臨牀研究表明，在體重管理方面具有優 | [Link](https://longbridge.com/en/news/276050786.md) |
| 東亞全年派息少 11.6% 李民斌強調派息比率 50% 盈利正常化後增股息 | 東亞銀行去年純利下跌 24% 至 35.01 億元，第二次中期股息減 42% 至每股 0.22 元，全年股息減 11.6% 至 0.61 元。股價一度急挫 13.8%。聯席執行長李民斌表示，盈利及股息減少主要因內地聯營公司及重估投資物業錄得 | [Link](https://longbridge.com/en/news/275882077.md) |
| SoFi 與 OSL 集團 (863) 達戰略合作，引入數字資產交易服務，業務首次擴張至美國本土以外市場 | SoFi Securities（香港）有限公司與 OSL 集團達成戰略合作，首次將數字資產交易服務擴展至美國以外市場。此合作為香港投資者提供通過 SoFi Hong Kong 應用程式交易多種數字資產的機會，標誌著 SoFi 全球業務的重要 | [Link](https://longbridge.com/en/news/275689746.md) |
| Global Partners（GLP）更高的季度分紅是否重新定義了其以收入為導向的投資故事？ | Global Partners LP 宣佈將於 2026 年 2 月 13 日支付 2025 年第四季度每單位現金分配 0.7600 美元。此決定反映了管理層對資本回報和單位持有者收入的關注。即將於 2026 年 2 月 27 日發佈的財報 | [Link](https://longbridge.com/en/news/275927197.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.